Pipeline
Endeavor
to Develop Medicines with Profound Clinical Benefit
© 2023 – Endeavor Biomedicines | Privacy Notice | Terms of Use
Pipeline
We are focused on developing transformative medicines by targeting the underlying genetic and cellular causes of disease with best-in-class agents.
Program
Preclinical
Phase 1
Phase 2
Phase 3
ENV-101
Oncology
Hedgehog Inhibitor
Phase 2
ENV-101
IPF
Hedgehog Inhibitor
Phase 2
ENV-501
Oncology
Antibody Drug Conjugate
Preclinical
ENV-101
ENV-101 is a small molecule Hedgehog signaling inhibitor that has demonstrated significant clinical efficacy and safety. We are developing ENV-101 as a targeted therapy for idiopathic pulmonary fibrosis (IPF) – where the Hedgehog pathway is implicated as a driver of the disease.
The clinical effects of ENV-101 have been evaluated in approximately 200 people. Six completed studies have characterized the pharmaceutical properties, including PK/PD in patients with advanced solid tumors and demonstrated a superior safety profile compared to similar therapeutics in this class
ENV-IPF-101
We are developing ENV-101 for patients with idiopathic pulmonary fibrosis (IPF), that has the potential to revolutionize the current standard of care (SoC). IPF is characterized by progressive lung scarring and reduction in lung volume. Pathologically, it is a wound that won’t heal.
Enrollment for this trial is currently closed.
For more information on our trial (NCT04968574): A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF).
ENV-501
ENV-501 is a next-generation HER3-targeted ADC with an exatecan payload that has been optimized for efficacy and safety. ENV-501 binds a novel epitope on the HER3 receptor, such that binding is unaffected by NRG1 (HER3 ligand) levels, allowing binding to HER3-expressing tumors even in high ligand contexts. An optimized Fc region that minimizes uptake by immune cells, combined with a stable conjugation profile with increased hydrophilicity, should enhance ENV-501’s safety profile. With these key proprietary technologies that improve efficacy while reducing side effects, we believe ENV-501 is positioned to become a best-in-class HER3 ADC.
ENV-ONC-501
We are developing ENV-501 for patients with HER3 expressing tumors. HER3 and HER2 are selectively upregulated receptors in many tumors that enable tumor survival and growth. HER3 is expressed more broadly and on different tumor types than HER2 enabling 501 to treat patients not currently treatable with HER2 therapies.
For more information on this trial and its enrollment please check this page or email us at EBMClinical@endeavorbiomedicines.com.
For more information about our clinical trials please contact us at:
Clinical Trials
IPF
Oncology
Expanded Access
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Egestas sed tempus urna et pharetra pharetra massa massa. Volutpat diam ut venenatis tellus in metus. Ullamcorper malesuada proin libero nunc consequat interdum varius. Fames ac turpis egestas maecenas pharetra convallis posuere. Hendrerit gravida rutrum quisque non. Pellentesque pulvinar pellentesque habitant morbi tristique senectus. Risus pretium quam vulputate dignissim suspendisse.
Quis risus sed vulputate odio ut. Quis eleifend quam adipiscing vitae proin sagittis. Volutpat diam ut venenatis tellus. Arcu dui vivamus arcu felis bibendum ut tristique et egestas. Massa vitae tortor condimentum lacinia quis vel eros donec ac. Tincidunt ornare massa eget egestas purus viverra. Congue eu consequat ac felis donec et odio. Gravida in fermentum et sollicitudin ac. Natoque penatibus et magnis dis parturient montes. Porttitor lacus luctus accumsan tortor posuere ac ut.